Nanobody Screening Services

Nanobody Screening Overview

 

In camelid animals, a unique type of heavy chain antibody naturally lacks both a light chain and a CH1 domain in the heavy chain. The variable region (VHH) of this heavy chain possesses complete binding capabilities, allowing it to independently bind to antigens. These remarkable antibodies are commonly known as nanobodies.

Leveraging our state-of-the-art flow cytometry sorting platform and the previously developed HC mouse model, our company is adept at providing swift and comprehensive nanobody screening services. Our platform encompasses every step of the process, from animal immunization and single B cell screening to sequence analysis and antibody expression. We offer a one-stop solution for nanobody screening, ensuring a seamless and efficient experience for our clients.

In camelid animals, a unique type of heavy chain antibody naturally lacks both a light chain and a CH1 domain in the heavy chain. The variable region (VHH) of this heavy chain possesses complete binding capabilities, allowing it to independently bind to antigens. These remarkable antibodies are commonly known as nanobodies.

All Antibody Discovery Services

Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.

Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.

Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.

Taking advantage of camelid-derived nanobodies, we present a distinct antibody structure providing exceptional therapeutic versatility. This innovation leads to innovative approaches to treatments and diagnostics and broadens the modern medical solutions.
In silico developability assessment, transforming biomedicine by providing groundbreaking approaches to predicting antibody developability. Leveraging advanced computational insights, streamline research processes, enhance therapeutic product robustness, and accelerate innovative drug discovery.
With our profound expertise, we optimize antibodies for human compatibility, boosting therapeutic outcomes. Reducing adverse reactions, we lay the groundwork for innovative, patient-focused personalized medicine, customized for each individual.
Our comprehensive assessment of drug potential and immune responses guarantees therapeutic safety and efficacy. This rigorous process is vital in bridging the transition from lab research to successful clinical stage implementation.
Using antibodies with high specificity, we guarantee precise binding targets for CAR-T cells and biologics. This meticulous approach is foundational to therapeutic success and patient outcomes. Promoting next-generation healthcare solutions.
Targeting G-protein coupled receptors, we access an expansive therapeutic domain. Concentrating on these essential proteins, we not only enhance drug efficacy but also pioneer breakthroughs, broadening horizons in modern drug development.
Nanobodies, featuring high affinity and stability, revolutionize therapeutic approaches. Their unique properties make them invaluable, especially in the areas of targeted drug delivery, advanced diagnostics, and innovative disease intervention strategies.
KYINNO sets the standard, prioritizing high-quality antibody production. We emphasize unmatched consistency, purity, and reliability, setting industry guidelines, fostering trust, and accelerating groundbreaking drug discovery and innovative research endeavors.
Bispecific antibodies from KY-CLC bind two distinct antigens, offering advanced therapeutic avenues, enhancing drug delivery, and increasing the potential for successful patient outcomes.
Nanobodies, known for their small molecular weight, high affinity, stability, permeability, and cost-effectiveness, have demonstrated tremendous potential in disease …